THE WOODLANDS, Texas, Jan. 6 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated announced today that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Lexicon, will speak at the 22nd Annual JPMorgan Healthcare Conference in San Francisco at 8:30 a.m. PST on Thursday, January 15, 2004. Dr. Sands will provide an overview of Lexicon, discuss its recently announced drug development collaboration with Bristol- Myers Squibb Company and review corporate objectives for 2004.
A live webcast of Dr. Sands’ presentation may be accessed on Lexicon’s corporate website at http://www.lexicon-genetics.com/ . An archived version of the webcast will be available on the website through January 23, 2004.
About Lexicon Genetics
Lexicon Genetics is a biopharmaceutical company focused on the discovery of breakthrough treatments for human disease. Lexicon is using gene knockout technology to systematically discover in living mammals, or in vivo, the physiological functions and pharmaceutical utility of genes. The Company’s gene function discoveries fuel therapeutic discovery programs in diabetes, obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. Lexicon has established drug discovery alliances and functional genomics collaborations with leading pharmaceutical and biotechnology companies, research institutes and academic institutions throughout the world to commercialize its technology and turn its discoveries into drugs. Additional information about Lexicon is available through its corporate website, http://www.lexicon-genetics.com/ .
Safe Harbor Statement
This press release contains “forward-looking statements,” including statements about Lexicon’s growth and future operating results, discovery and development of products, strategic alliances, and intellectual property, as well as other matters that are not historical facts or information. These forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon’s ability to develop drug candidates from its discoveries, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, that may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Factors Affecting Forward-Looking Statements” and “Business -- Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2002, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
Lexicon Genetics Incorporated
CONTACT: Chas Schultz, Director, Investor Relations and FinancialAnalysis of Lexicon Genetics Incorporated, +1-281-863-3421, orcschultz@lexgen.com
Web site: http://www.lexicon-genetics.com/
